Great Point Partners LLC 13F Holdings · Q2 2026
Great Point Partners LLC reported 37 securities worth $529.12M in its SEC 13F filing for Q2 2026 (period ended 2026-06-30). Top holdings: ABVX (15.22%), VOR (5.91%), IBRX (4.97%). Among its top 25 positions this quarter: 5 new, 7 added, 6 trimmed.
| Rank | Ticker | Company | Value | % Portfolio | Shares | Action |
|---|---|---|---|---|---|---|
| 1 | ABVX | ABIVAX SA | $80.5M | 15.22% | 604,314 | New |
| 2 | VOR | VOR BIOPHARMA INC | $31.3M | 5.91% | 1.7M | Trimmed |
| 3 | IBRX | IMMUNITYBIO INC | $26.3M | 4.97% | 3.0M | Hold |
| 4 | VERA | VERA THERAPEUTICS INC | $25.8M | 4.87% | 600,836 | Added |
| 5 | ZURA | ZURA BIO LTD | $24.9M | 4.70% | 4.2M | Hold |
| 6 | ALMS | ALUMIS INC | $24.1M | 4.55% | 856,061 | Hold |
| 7 | SLGL | SOL-GEL TECHNOLOGIES LTD | $20.3M | 3.84% | 274,363 | Hold |
| 8 | RARE | ULTRAGENYX PHARMACEUTICAL IN | $20.0M | 3.79% | 600,000 | New |
| 9 | ANNX | ANNEXON INC | $20.0M | 3.78% | 3.5M | Added |
| 10 | DFTX | DEFINIUM THERAPEUTICS INC | $20.0M | 3.78% | 425,000 | New |
| 11 | ORKA | ORUKA THERAPEUTICS INC | $17.4M | 3.30% | 183,330 | Hold |
| 12 | MLTX | MOONLAKE IMMUNOTHERAPEUTICS | $16.7M | 3.15% | 855,813 | Added |
| 13 | SGMT | SAGIMET BIOSCIENCES INC | $15.7M | 2.97% | 2.0M | New |
| 14 | CTNM | CONTINEUM THERAPEUTICS INC | $15.1M | 2.85% | 921,481 | Added |
| 15 | IMMX | IMMIX BIOPHARMA INC | $13.2M | 2.49% | 1.3M | Added |
| 16 | CLYM | CLIMB BIO INC | $13.0M | 2.46% | 1.0M | Trimmed |
| 17 | AMLX | AMYLYX PHARMACEUTICALS INC | $12.6M | 2.38% | 700,000 | Trimmed |
| 18 | NKTR | NEKTAR THERAPEUTICS | $12.2M | 2.31% | 175,000 | Trimmed |
| 19 | NGNE | NEUROGENE INC | $11.1M | 2.09% | 352,180 | Trimmed |
| 20 | LBRX | LB PHARMACEUTICALS INC | $10.3M | 1.95% | 317,221 | Added |
| 21 | IRD | OPUS GENETICS INC | $8.1M | 1.53% | 2.0M | Added |
| 22 | EPRX | EUPRAXIA PHARMACEUTICALS INC | $7.9M | 1.50% | 1.2M | Hold |
| 23 | DRUG | BRIGHT MINDS BIOSCIENCES INC | $7.7M | 1.45% | 109,603 | Trimmed |
| 24 | IFRX | INFLARX NV | $6.8M | 1.29% | 3.0M | New |
| 25 | RLMD | RELMADA THERAPEUTICS INC | $5.8M | 1.10% | 842,106 | Hold |
Source: SEC Form 13F filings · as of 2026-06-30
Every position in this 13F-HR, with its change from the prior quarter.
13F holdings, latest quarter
SourceSEC EDGAR13F-HR